Intrommune Therapeutics, Inc. is a biotechnology company located in New York, NY. Intrommune is developing food allergy immunotherapies that are delivered while you brush your teeth, a lifelong habit that is ingrained in most people and ensures daily use of our product. Intrommune's elegant new treatment platform for food allergies is expected to be safe, effective and convenient. Intrommune’s first product is a therapy for patients who suffer from peanut allergy. Intrommune is developing the oral mucosal immunotherapy (OMIT) platform for food allergies. It is a long-term solution for the 220 million, including 32 million people in the U.S., who suffer from this life-altering condition.